Pricing
  1. JP-listed companies
  2. COSMO BIO COMPANY, LIMITED
  3. Financials
  4. Revenue growth (%)

COSMO BIO COMPANY, LIMITED【JP:3386】

Market cap
¥7.9B
P/E ratio
33.8x
Cosmo Bio imports and sells life science research reagents and equipment to researchers at universities and corporations, offering over 10 million products from 500 companies worldwide.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndRevenue growth (%) YoY (%)
Dec 31, 20257.3-2.68%
Dec 31, 20247.5-434.53%
Dec 31, 2023-2.2-163.90%
Dec 31, 20223.5-75.21%
Dec 31, 202114.1+113.01%
Dec 31, 20206.6+45.92%
Dec 31, 20194.5+65.93%
Dec 31, 20182.7-156.52%
Dec 31, 2017-4.8-608.42%
Dec 31, 20161-43.79%
Dec 31, 20151.7-35.50%
Dec 31, 20142.6-199.24%
Dec 31, 2013-2.6-488.24%
Dec 31, 20120.7

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)